Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Rating of “Hold” from Brokerages

Seres Therapeutics, Inc. (NASDAQ:MCRB) has been given a consensus rating of “Hold” by the five research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $4.00.

MCRB has been the subject of several recent analyst reports. The Goldman Sachs Group decreased their price objective on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a report on Friday, March 14th. StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th.

Institutional Trading of Seres Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its position in Seres Therapeutics by 42.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after buying an additional 222,771 shares during the last quarter. FMR LLC boosted its stake in shares of Seres Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after acquiring an additional 140,096 shares in the last quarter. Providence Wealth Advisors LLC grew its holdings in shares of Seres Therapeutics by 29.2% in the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 22,250 shares during the last quarter. State Street Corp raised its position in shares of Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 43,700 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Seres Therapeutics by 22.5% during the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after purchasing an additional 255,014 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors.

Seres Therapeutics Stock Up 1.2 %

MCRB stock opened at $0.75 on Friday. The company has a 50-day simple moving average of $0.79 and a 200 day simple moving average of $0.83. The company has a market capitalization of $130.01 million, a P/E ratio of -3.25 and a beta of 2.19. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $1.53.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.